Novartis Acquires Tourmaline Bio for Cardiovascular Therapy Development
Novartis acquires Tourmaline Bio for $1.4B, gaining pacibekitug, a Phase 3-ready anti-inflammatory drug for heart disease (ASCVD), targeting IL-6. This boosts Novartis's cardiovascular pipeline, addressing unmet needs in reducing residual inflammatory risk.